Greenwich LifeSciences, Inc (GLSI) - Forward P/S Multiple

Greenwich LifeSciences (GLSI) is developing the breakthrough GP2 vaccine against breast cancer recurrence by investing in bioengineering. The forward P/S multiple reflects market expectations, with the indicator reaching . While decisive management is striving for the drug's success, the lack of profitability and reliance on external investment during Phase III trials are creating financial pressure.

For Greenwich LifeSciences (GLSI), whose current GP2 immunotherapy development costs are already priced in by the market, the commercialization of Phase 3 trial results will serve as the key driver. The forward P/S ratio relates current market capitalization to expected annual revenue, allowing investors to assess the degree of overvaluation relative to future sales, a trend clearly demonstrated by the forward P/S history.